Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scans may reveal why nerves die in MS

NCT ID NCT04532944

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study used advanced MRI scans to look at energy use in the brains of 40 people with multiple sclerosis and 15 healthy volunteers. The goal was to see if energy problems in brain cells can predict nerve damage over two years. Researchers hope this will help understand how MS causes disability and lead to better treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify early signs of nerve damage in MS, guiding future treatments to protect the brain.
What could go wrong
This is an observational imaging study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all MS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for MS: 1. RR-MS patients with a disease duration of less than 10 years: * 18-55 years * clinically defined RR-MS according to the 2017 revised McDonald's criteria (MS diagnostic criteria 2017) * disease duration \<10 years * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent 2. Patients with progressive MS (primary or secondary) of less than 10 years: * 18-55 years * clinically defined progressive MS according to the 2017 revised McDonald's criteria * disease duration \<10 years from the beginning of the progressive phase * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent Inclusion Criteria for healthy controls: * 18-55 years (matched with patients) * no known general pathologies * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent Exclusion Criteria for MS: * Pregnant or breastfeeding women * Last infusion of cyclophosphamide, mitoxantrone or methylprednisolone realized less than 1 month before inclusion * last clinical relapse less than one month before inclusion * severe cardiac, pulmonary, hepatic, hematologic renal, gastrointestinal disease, or cancer * contraindications to MRI: claustrophobia, pace-maker implant, any surgical ferromagnetic clips, ocular implants, any intraocular or intracranial metallic fragments, any metallic objects able to concentrate the radiofrequency field, cochlear implants, cardiac or brain stimulators, any tattoos or permanent makeup on the face, renal failure (exclusion criterion for gadolinium injection) patients not willing to be informed of any possible cerebral malformations incidentally discovered at the MRI exam * severe renal failure (clearance of creatinine \< 30ml/min) * history of allergic reactions to gadolinium salts * any other chronic neurological disorders associated * persons deprived of liberty by law or by administrative decision * Persons under legal protection Exclusion Criteria for healthy controls: * Pregnant or breastfeeding women * severe cardiac, pulmonary, hepatic, hematologic renal, gastrointestinal disease, or cancer * contraindications to MRI : claustrophobia, pace-maker implant, any surgical magnetic clips, ocular implants, any intraocular or intracranial metallic fragments, any metallic objects able to concentrate the radiofrequency field, cochlear implants, cardiac or brain stimulators, any tattoos or permanent makeup on the face * person not willing to be informed of any possible cerebral malformations incidentally discovered at the MRI exam * associated chronic neurological disorders * persons deprived of liberty by law or by administrative decision * Persons under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICM, Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.